DexCom(US:DXCM) Globenewswire·2025-11-19 21:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging misleading statements and undisclosed material changes to the company's glucose monitoring products, G6 and G7, which may have health implications for users [1][3]. Group 1: Allegations - The complaint claims that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable and posed health risks to users [3]. - It is alleged that the enhancements to the G7's reliability, accuracy, and functionality were overstated, and the company downplayed the severity of issues related to the G7 devices [3]. - The lawsuit suggests that these actions increased the risk of regulatory scrutiny and could lead to significant legal, reputational, and financial harm for DexCom [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, with a deadline for shareholders to register as lead plaintiffs by December 26, 2025 [3][4]. - Shareholders who register will receive updates on the case's progress through a portfolio monitoring software, and participation in the case incurs no cost or obligation [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].